Kidswell Bio Corporation (4584)

Market cap
¥12B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
Period EndRetained earnings (Million JPY)YoY (%)
Mar 31, 2025-12,730+0.17%
Mar 31, 2024-12,709+12.60%
Mar 31, 2023-11,287+6.34%
Mar 31, 2022-10,614+5.31%
Mar 31, 2021-10,079+11.03%
Mar 31, 2020-9,077+415.50%
Mar 31, 2019-1,761+94.66%
Mar 31, 2018-905-81.23%
Mar 31, 2017-4,819+34.07%
Mar 31, 2016-3,594+28.07%
Mar 31, 2015-2,807
AI Chat